Development of efficient disease-regulated expression cassettes for gene therapy using microRNA targeting sequences
使用 microRNA 靶向序列开发用于基因治疗的有效疾病调节表达盒
基本信息
- 批准号:BB/F006667/1
- 负责人:
- 金额:$ 42.99万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2008
- 资助国家:英国
- 起止时间:2008 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Gene therapy, the use of nucleic acid material (e.g. DNA, RNA), is being developed to treat a number of diseases that are currently difficult to treat with conventional drugs. Although there are a large number of candidate therapeutic genes a major problem has been the safe and efficient delivery of the gene into target cells and tissues in order to achieve appropriate levels of the gene for long enough to treat the disease. Once a therapeutic gene has been identified, the first step is to develop an 'expression cassette'. The expression cassette is the gene linked to DNA sequences required to 'switch on' the gene, termed 'transcription'. One of the limitations to achieving successful gene therapy has been how well the gene is expressed once inside a cell. Most genes are expressed at high levels, in all cell types and sometimes this results in gene transcription being switched off because the cell identifies the expression cassette as 'foreign', or transcription is too high and is toxic to the cell because it is expressed all the time, not just when the disease is active. For cells to function normally they use several methods to switch their own genes on and off and this allows different cells in different tissues/ organs to perform their normal functions and respond to changes which make them function abnormally (e.g. disease). The methods used by cells include DNA on/ off switches called 'promoters' which are only found in one cell type (e.g. liver cells, heart cells, or blood cells). Also, recently a new gene expression controlling pathway has been found termed 'RNA interference' which 'tidies up' gene expression to ensure it is even more specific between different cell types. Importantly recent papers have indicated that this pathway is important in controlling cell's own gene expression while they are growing and also during disease. In this proposal I seek to improve gene therapy expression cassettes by using promoters and the RNA interference gene 'on/ off' system, so the gene is only switched on when disease is active in the cells. RNA interference has very recently been shown to be important in the regulation of genes during a disease termed cardiac hypertrophy (heart enlargement). Therefore, as proof of concept for using these identified RNA interference 'switches' I will make gene delivery expression cassettes to express genes only in heart cells undergoing hypertrophy. Importantly, I will use a virus vector which can efficiently deliver genes to these heart cells in vivo and test the concept in an animal model of in which heart enlargement take place. This takes advantage of our recent knowledge of RNA interference and its function in hypertrophy, the availability of an ideal gene delivery vector to deliver the gene to the correct cell type (heart cells) in an ideal model. This work will provide proof of concept for the use of RNA interference to switch on transgene expression in a specific disease situation, however the concepts will be applicable to the development of gene therapies aimed at many different cell types in many different diseases in the future.
基因疗法,即使用核酸材料(例如DNA、RNA),正在被开发用于治疗目前难以用常规药物治疗的许多疾病。尽管有大量的候选治疗基因,但主要问题是将基因安全有效地递送到靶细胞和组织中,以便在足够长的时间内达到适当的基因水平以治疗疾病。一旦确定了治疗基因,第一步就是开发“表达盒”。表达盒是连接到DNA序列的基因,该DNA序列被称为“转录”,是“启动”基因所需的。实现成功的基因治疗的限制之一是基因在细胞内表达的程度。大多数基因在所有细胞类型中都以高水平表达,有时这会导致基因转录被关闭,因为细胞将表达盒识别为“外源”,或者转录太高并且对细胞有毒,因为它一直表达,而不仅仅是在疾病活跃时。为了使细胞正常发挥功能,它们使用几种方法来打开和关闭自己的基因,这使得不同组织/器官中的不同细胞能够执行其正常功能,并对使它们功能异常的变化(例如疾病)做出反应。细胞使用的方法包括称为“启动子”的DNA开/关开关,其仅在一种细胞类型(例如肝细胞、心脏细胞或血细胞)中发现。此外,最近发现了一种新的基因表达控制途径,称为“RNA干扰”,它“整理”基因表达,以确保它在不同细胞类型之间更具特异性。重要的是,最近的论文表明,这一途径在细胞生长和疾病期间控制细胞自身基因表达方面很重要。在这个提议中,我试图通过使用启动子和RNA干扰基因“开/关”系统来改进基因治疗表达盒,因此只有当疾病在细胞中活跃时,基因才被打开。RNA干扰最近已被证明是重要的基因调控过程中的疾病称为心脏肥大(心脏扩大)。因此,作为使用这些鉴定的RNA干扰“开关”的概念证明,我将使基因递送表达盒仅在经历肥大的心脏细胞中表达基因。重要的是,我将使用一种病毒载体,它可以有效地将基因传递到体内的这些心脏细胞中,并在心脏扩大发生的动物模型中测试这个概念。这利用了我们最近对RNA干扰及其在肥大中的功能的了解,理想的基因递送载体的可用性,以在理想的模型中将基因递送到正确的细胞类型(心脏细胞)。这项工作将为在特定疾病情况下使用RNA干扰来开启转基因表达提供概念证明,然而,这些概念将适用于未来针对许多不同疾病中许多不同细胞类型的基因疗法的开发。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pathological increase in left ventricular mass index and changing microRNA profile in stroke prone spontaneously hypertensive rats.
易发生卒中的自发性高血压大鼠左心室质量指数病理性增加和 microRNA 谱变化。
- DOI:
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Monkevicuite A
- 通讯作者:Monkevicuite A
Development of cardiac hypertrophy regulated expression cassettes using miRNA targeting sequences.
使用 miRNA 靶向序列开发心脏肥大调节表达盒。
- DOI:
- 发表时间:2010
- 期刊:
- 影响因子:4.2
- 作者:Haggerty C
- 通讯作者:Haggerty C
Development of tissue-specific expression cassettes using miRNA targeting sequences for cardiac gene therapy
使用 miRNA 靶向序列开发用于心脏基因治疗的组织特异性表达盒
- DOI:
- 发表时间:2011
- 期刊:
- 影响因子:4.2
- 作者:Haggerty C
- 通讯作者:Haggerty C
Tropism-modification strategies for targeted gene delivery using adenoviral vectors.
- DOI:10.3390/v2102290
- 发表时间:2010-10
- 期刊:
- 影响因子:0
- 作者:Coughlan L;Alba R;Parker AL;Bradshaw AC;McNeish IA;Nicklin SA;Baker AH
- 通讯作者:Baker AH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stuart Nicklin其他文献
J. Zhang and G. Rokosh (eds): Cardiac Gene Expression, Methods in Molecular Biology Series, Vol. 366
- DOI:
10.1007/s12033-007-0067-4 - 发表时间:
2007-08-07 - 期刊:
- 影响因子:2.500
- 作者:
Stuart Nicklin - 通讯作者:
Stuart Nicklin
Stuart Nicklin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stuart Nicklin', 18)}}的其他基金
Angiotensin-(1-7) and angiotensin-(1-9): assessment as therapeutic targets in acute vascular injury and remodelling
血管紧张素-(1-7) 和血管紧张素-(1-9):作为急性血管损伤和重塑治疗靶点的评估
- 批准号:
MR/L019108/1 - 财政年份:2014
- 资助金额:
$ 42.99万 - 项目类别:
Research Grant
Dissecting the mechanism of action of the renin angiotensin hormone angiotensin1-9
剖析肾素血管紧张素激素 angiotensin1-9 的作用机制
- 批准号:
G0901161/1 - 财政年份:2010
- 资助金额:
$ 42.99万 - 项目类别:
Research Grant
相似国自然基金
固定参数可解算法在平面图问题的应用以及和整数线性规划的关系
- 批准号:60973026
- 批准年份:2009
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Development of ultra-efficient antibodies for single cell mapping applications
开发用于单细胞作图应用的超高效抗体
- 批准号:
10601458 - 财政年份:2023
- 资助金额:
$ 42.99万 - 项目类别:
Development of an Efficient High Throughput Technique for the Identification of High-Impact Non-Coding Somatic Variants Across Multiple Tissue Types
开发一种高效的高通量技术,用于鉴定跨多种组织类型的高影响力非编码体细胞变异
- 批准号:
10662860 - 财政年份:2023
- 资助金额:
$ 42.99万 - 项目类别:
Development and validation of efficient cognitive composite scores of digital tools for the detection of early pathophysiological changes in Alzheimers disease
开发和验证数字工具的有效认知综合评分,用于检测阿尔茨海默病的早期病理生理变化
- 批准号:
10642370 - 财政年份:2023
- 资助金额:
$ 42.99万 - 项目类别:
Development of Efficient Carbon Carbon Bond Formations for Novel Se-, S-, and O-Heterocycle Synthesis
用于新型 Se-、S- 和 O-杂环合成的高效碳碳键形成的开发
- 批准号:
10683083 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
Development of an acute myeloid leukemia murine model of invasive pulmonary aspergillosis to gain insights into the role of leukemia and its treatments in the pathobiology of aspergillosis
开发侵袭性肺曲霉病的急性髓系白血病小鼠模型,以深入了解白血病及其治疗在曲霉病病理学中的作用
- 批准号:
10524878 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
PFI-TT: Development of an Automated Cell Culturing Platform for Highly Efficient and Reliable Drug Testing in Physiologically Representative Disease Models
PFI-TT:开发自动化细胞培养平台,在生理代表性疾病模型中进行高效可靠的药物测试
- 批准号:
2141029 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
Standard Grant
Development of NAD+ loaded nanoparticles as a safe and efficient strategy to combat sepsis.
开发负载 NAD 的纳米粒子作为对抗脓毒症的安全有效策略。
- 批准号:
10448923 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
Development of a Portable Ion Mobility Spectrometer For Efficient Diagnosis of Various Diseases
开发便携式离子淌度光谱仪以有效诊断各种疾病
- 批准号:
10708021 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
Development of Efficient Carbon Carbon Bond Formations for Novel Se-, S-, and O-Heterocycle Synthesis
用于新型 Se-、S- 和 O-杂环合成的高效碳碳键形成的开发
- 批准号:
10412238 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别:
Development of a telehealth medication-assisted treatment (MAT) system for patients with opioid use disorder (OUD)
为阿片类药物使用障碍 (OUD) 患者开发远程医疗药物辅助治疗 (MAT) 系统
- 批准号:
10322290 - 财政年份:2022
- 资助金额:
$ 42.99万 - 项目类别: